In response to COVID-19, GHX is committed to helping ensure that our customers receive access to the data and information needed to help maintain critical supplies to serve patients and protect staff. Click to learn more
Log In

Approved in June 2018 for treatment of chronic lymphocytic leukemia (CLL), venetoclax has generated excitement over the possibility of fixed-duration treatment. In this short video, Lumere looks at the evidence resulting from the associated Phase III clinical trials.

 

A Deeper Dive for Clients Only: What Does the Evidence Say?

Lumere’s research team puts it’s expertise to use collecting the relevant literature and trials and synthesizing each drug’s evidence, prescribing information, and safety and attribute data into one, easy-to-digest source.

Targeted antineoplastics for chronic lymphocytic leukemia

Targeted agents for acute myeloid leukemia

Talk to an Expert

Need to understand historical drug utilization? Embarking on a new initiative? Preparing for an upcoming P&T meeting? You have access to Lumere’s experts at Explore@Lumere.com.